Navigation Links
European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
Date:2/6/2013

is (DVT) and/or pulmonary embolism (PE)) across approximately 400 recruiting hospitals and specialised centres, in seven major European countries (Austria, France, Germany, Italy, Spain, Switzerland and the UK). By collecting key data from different geographies, the registry will highlight important risk factors, as well as demonstrate diagnosis pathways and treatment modalities in this patient population. The review of current therapy and healthcare resource use will allow an evaluation of the relationship between the use of anticoagulants and approximate therapy costs. In contrast to other registries in this setting, PREFER in VTE is the first of its kind to also analyse the relationship between VTE treatment, a patient's quality of life and treatment satisfaction.

In 2012, Daiichi Sankyo Europe GmbH started another large registry, focussing on patients suffering from atrial fibrillation (AF) - the PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). The company has now completed the enrolment of more than 7,100 patients who will be followed up for 12 months. The first set of data will be available in the summer of 2013.

The PREFER in VTE and PREFER in AF registries reinforce Daiichi Sankyo's leadership in cardiovascular medicine.[3] Dr. Jan van Ruymbeke , CEO of Daiichi Sankyo Europe GmbH, stated, "Daiichi Sankyo is committed to improve patient outcomes which means applying our expertise and innovation to provide best- in-class medicine for our patients."

Daiichi Sankyo discovered and is currently studying edoxaban, a novel once-daily oral factor Xa inhibitor, as a potential new treatment option for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... POH, AIM: PSG, OTCQX: PPGNY) today announced that, ... Phase 1 transdermal,oxycodone clinical trial aimed at providing ... Phosphagenics has submitted all necessary documents for ... at CMAX - an independent clinical research,organization located ...
... First internal candidate to enter Phase 2 clinical ... PCOP ), an innovator in the discovery ... the initiation of a Phase 2a,clinical study of ... a dual-acting angiotensin and endothelin receptor antagonist,(DARA) that ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:5/24/2013)... 24 (HealthDay News) -- New research suggests a ... people with insomnia. Every additional hour someone ... percent drop in the likelihood of moderate or ... the University of Pennsylvania. "We were ... sleep duration and suicide risk," study author, Linden ...
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Area homeowners dreaming ... of new hot tubs to choose from at factory-direct pricing ... . The sales event takes place at Emerald Pool ... 2013. , Jacuzzi, the industry's leading hot tub brand, ... across the country. The event will feature popular hot tub ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Jan. 13 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... the main preliminary indicators obtained at the close of ... slightly lower results than the,original growth expectations. However, product ... line with original projections. , ...
... welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State ... representatives and other dignitaries for the construction dedication ... 13 Today, Grifols SA (Grifols), a global ... Los Angeles Mayor Antonio Villaraigosa., Cal State LA ...
... WASHINGTON, Jan. 13 Speaker Nancy Pelosi released ... bipartisan legislation to expand the State Children,s Health ... Similar bipartisan legislation was vetoed twice by President ... bill, click here http://www.speaker.gov/newsroom/legislation?id=0270: "Today, the House ...
... The following was released today by the Office of the ... , On Wednesday, ... Health Insurance Program (SCHIP) Reauthorization bill. This bipartisan bill ... 11 million children -- preserving coverage for the 7 ...
... SRA International, Inc. (NYSE: SRX ), ... and solutions to government organizations and commercial clients, will ... release after close of market on Thursday, Feb. 5, ... call beginning at 5 p.m. EST.Interested parties may listen ...
... helped with pain, fatigue and depression, study shows ... may help people living with the chronic pain ... quality of life, new research shows. , The ... Saarbrucken in Germany, found that fibromyalgia patients had ...
Cached Medicine News:Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 3Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 4Health News:SRA Schedules Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: